• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Fiercest Competition in Kinase Inhibitor Drug Development is Found in Hematological, Breast, Lung, Prostate and Colorectal Cancer

Posted on: Thursday, 24 August 2006, 12:00 CDT

Research and Markets (http://www.researchandmarkets.com/reports/c40986) has announced the addition of Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies to their offering.

In this triple analysis report we have analyzed three major and intertwined areas of cancer R&D, Lymphoma, Protein Kinase Inhibitors and Therapeutic Antibodies, which are all subjects to an extensive number of innovative drug candidates. This extensive 320 pages report compiles and analyzes the progress concerning drug development and competitive situation in the three mentioned key oncology areas. The report will not only provide a framework but also a careful identification and evaluation of drug candidates, technologies and competitors.

Published trial data show an increase in response rates when rituximab is combined with current chemotherapy regimens in both the first- and second-line settings in the treatment of lymphoma. In addition, rituximab show significant off-label usage. Already today it is clear that rituximab has generated substantial revenues for the companies involved in its development. A collection of emerging facts suggest that several of the new targeted therapies under development include agents that cannot just be added into treatment regimens with conventional drugs. A few of them might have isolated properties on certain biologic targets that may require to be modulated in particular ways before or after cytotoxic chemotherapy. Among the emerging therapeutic strategies, passive and active immunotherapies have clearly continued to be leading strategies. Small molecule kinase inhibitors are as well in the forefront.

The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs.

The number of protein kinase inhibitor drugs has risen sharply, as the number of targets. The fiercest competition in kinase inhibitor drug development is found in hematological, breast, lung, prostate, and colorectal cancer. Several big pharma companies are out hunting for promising technology and drugs to complement their internal pipeline.

Scope of this report

-- Status and impact of several novel drugs in development: The

lymphoma indication in specific and protein kinase inhibitors

and antibodies in oncology in general

-- Discussion of the challenges in current lymphoma treatment

strategies.

-- Thorough examination of the top cancer therapeutic strategies

on the market

-- Description of the race towards the next generation of

therapeutics

-- Discussion of the challenges in current drug development,

including future clinical trials to be made, collaborations

and inclusion of novel endpoints.

-- Competitive landscape assessment

-- Thorough review of the largest cancer indications.

-- Drugs according to targets

-- Targets according to indication

Key reasons to read this report

-- Gain insight into the current challenges and commercial

opportunities in lymphoma treatment in specific and protein

kinase inhibitors and antibodies in oncology in general.

-- One source to the top cancer therapeutic on the market

-- Key insights into the second wave in the lucrative field of

antibody therapeutics and the promising development of protein

kinase inhibitors

-- Competitive landscape assessment, including deals,

technologies and drug development.

-- Assess opportunities and risks for the continued development

of innovative developmental treatments

-- Adopt knowledge from this analysis to drive strategic planning

decisions in oncology drug development

The Companies Mentioned inside Report: - Accentia BioPharmaceuticals - Biogen Idec - Cell Therapeutics - Chiron Corporation - Cephalon - Eli Lilly - Favrille - Genentech - Genitope Corporation - Genmab - Genta - GlaxoSmithKline - Immunomedics - Inex Pharmaceuticals - Millennium Pharmaceuticals - Protein Design Labs - Roche - Sanofi-Aventis - Seattle Genetics - Wyeth

For more information visit http://www.researchandmarkets.com/reports/c40986

Source: Business Wire

More News in this Category